Cas:951238-13-4 5-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]pyridin-2-amine manufacturer & supplier

Chemical Name:5-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]pyridin-2-amine

CAS.NO:951238-13-4

Synonyms:5-(2-(trifluoromethyl)-5-methoxy-1h-benzo[d]imidazol-1-yl)pyridin-2-amine

Molecular Formula:C₁₄H₁₁F₃N₄O

Molecular Weight:308.25900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:66.69000

Exact Mass:308.08800

LogP:2.96020

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-(2-(trifluoromethyl)-5-methoxy-1h-benzo[d]imidazol-1-yl)pyridin-2-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(2-(trifluoromethyl)-5-methoxy-1h-benzo[d]imidazol-1-yl)pyridin-2-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(2-(trifluoromethyl)-5-methoxy-1h-benzo[d]imidazol-1-yl)pyridin-2-amine Use and application,5-(2-(trifluoromethyl)-5-methoxy-1h-benzo[d]imidazol-1-yl)pyridin-2-amine technical grade,usp/ep/jp grade.

Related News: The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. 5-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]pyridin-2-amine manufacturer Some of Amanpour’s counterparts also offered well-wishes on Monday. 5-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]pyridin-2-amine supplier Also, the study did not compare people who had COVID-19 with those who did not, to see if such symptoms were higher than in the general population. The report did exclude patients with certain serious or chronic preexisting conditions like cancer, kidney disease, HIV, liver disease and stroke, to separate their previous health status from post-COVID symptoms. 5-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]pyridin-2-amine vendor The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market. 5-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]pyridin-2-amine factory Some of Amanpour’s counterparts also offered well-wishes on Monday.